These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 15279897)

  • 1. Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia.
    Ito A; Kuga Y; Honda H; Kikkawa H; Horiuchi A; Watanabe Y; Kobayashi T
    Cancer Lett; 2004 Aug; 212(2):167-75. PubMed ID: 15279897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-cancer effect of hyperthermia on breast cancer by magnetite nanoparticle-loaded anti-HER2 immunoliposomes.
    Kikumori T; Kobayashi T; Sawaki M; Imai T
    Breast Cancer Res Treat; 2009 Feb; 113(3):435-41. PubMed ID: 18311580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
    Kirpotin DB; Drummond DC; Shao Y; Shalaby MR; Hong K; Nielsen UB; Marks JD; Benz CC; Park JW
    Cancer Res; 2006 Jul; 66(13):6732-40. PubMed ID: 16818648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
    Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
    Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
    Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D
    Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple Therapy of HER2
    Zolata H; Afarideh H; Davani FA
    Cancer Biother Radiopharm; 2016 Nov; 31(9):324-329. PubMed ID: 27831759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective death of human breast cancer cells by lytic immunoliposomes: Correlation with their HER2 expression level.
    Barrajón-Catalán E; Menéndez-Gutiérrez MP; Falco A; Carrato A; Saceda M; Micol V
    Cancer Lett; 2010 Apr; 290(2):192-203. PubMed ID: 19896266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy.
    Eloy JO; Petrilli R; Chesca DL; Saggioro FP; Lee RJ; Marchetti JM
    Eur J Pharm Biopharm; 2017 Jun; 115():159-167. PubMed ID: 28257810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer.
    Kubo M; Morisaki T; Kuroki H; Tasaki A; Yamanaka N; Matsumoto K; Nakamura K; Onishi H; Baba E; Katano M
    Anticancer Res; 2003; 23(6a):4443-9. PubMed ID: 14666732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo anti-cancer efficacy of magnetite nanocrystal--based system using locoregional hyperthermia combined with 5-fluorouracil chemotherapy.
    Li TJ; Huang CC; Ruan PW; Chuang KY; Huang KJ; Shieh DB; Yeh CS
    Biomaterials; 2013 Oct; 34(32):7873-83. PubMed ID: 23876757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific anti-HER2 and CD16 single-chain antibody production prolongs the use of stem cell-like cell transplantation against HER2-overexpressing cancer.
    Kasuya K; Shimazu M; Suzuki M; Itoi T; Aoki T; Tsuchida A
    Int J Mol Med; 2010 Feb; 25(2):209-15. PubMed ID: 20043129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoliposome encapsulation increases cytotoxic activity and selectivity of curcumin and resveratrol against HER2 overexpressing human breast cancer cells.
    Catania A; Barrajón-Catalán E; Nicolosi S; Cicirata F; Micol V
    Breast Cancer Res Treat; 2013 Aug; 141(1):55-65. PubMed ID: 23959397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab Conjugated Superparamagnetic Iron Oxide Nanoparticles Labeled with
    Cędrowska E; Pruszyński M; Gawęda W; Żuk M; Krysiński P; Bruchertseifer F; Morgenstern A; Karageorgou MA; Bouziotis P; Bilewicz A
    Molecules; 2020 Feb; 25(5):. PubMed ID: 32106568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.
    Baselga J; Norton L; Albanell J; Kim YM; Mendelsohn J
    Cancer Res; 1998 Jul; 58(13):2825-31. PubMed ID: 9661897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
    Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
    Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production.
    Simeone AM; Broemeling LD; Rosenblum J; Tari AM
    Oncogene; 2003 Oct; 22(43):6739-47. PubMed ID: 14555987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles.
    Anhorn MG; Wagner S; Kreuter J; Langer K; von Briesen H
    Bioconjug Chem; 2008 Dec; 19(12):2321-31. PubMed ID: 18937508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.